The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | MRD as a surrogate endpoint: what remains for FDA approval?
Faith Davies, MBBCh, MRCP, MD, FRCPath, from NYU Langone Medical Center, New York, NY, chairs a session at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, with Maria-Victoria Mateos, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, and Nikhil Munshi, MD, from Dana-Farber Cancer Institute, Boston, MA. The speakers discuss what data the FDA need to be able to think about measurable residual disease (MRD) as a surrogate endpoint for progression-free survival.
